Trontinemab

DRUG4 trials

Sponsors

F. Hoffmann-La Roche AG, Hoffmann-La Roche

Conditions

Alzheimer's DiseaseAlzheimer's diseaseAlzheimers Disease

Phase 1

A Phase IB/IIA, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 following Intravenous Infusion in Patients with Prodromal or Mild To Moderate Alzheimer’s Disease

RecruitingCTIS2023-509678-52-00

F. Hoffmann-La Roche AGAlzheimer's disease

Start: 2024-06-27Target: 99Updated: 2026-01-09

Phase 3

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

RecruitingNCT07169578

Hoffmann-La RocheAlzheimers Disease

Start: 2025-09-17End: 2028-06-07Target: 800Updated: 2026-08-06

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

RecruitingNCT07170150

Hoffmann-La RocheAlzheimers Disease

Start: 2025-11-12End: 2028-06-07Target: 800Updated: 2026-08-06

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

RecruitingNCT07717411

Hoffmann-La RocheAlzheimer's Disease

Start: 2026-11-30End: 2032-09-03Target: 1600Updated: 2026-09-10